

FORM PTO 1449
(REV. 7-80)

JUL 19 2007

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CON2SERIAL NO.:
10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use additional sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

/JHAA/	AJ	Philip D. Kanof et al., "Levels of Opioid Physical Dependence in Heroin Addicts," Drug and Alcohol Dependence, 27 (1991) 253-262.
/JHAA/	AK	J.E. Peachey et al., "Assessment of Opioid Dependence with Naloxone," British Journal of Addiction (1988) 83(2), 193-201
/JHAA/	AL	John G. Nutt et al., "Methadone-naloxone Mixtures for Use in Methadone Maintenance Programs," Clinical Pharmacology and Therapeutics, Vol. 15, Number 2, pp. 156-166, received for publication June 11, 1973
/JHAA/	AM	Richard I. H. Wang et al., "Rating the Presence and Severity of Opiate Dependence," Clinical Pharmacology and Therapeutics, Volume 16, Number 4, pp. 653-657; received for publication January 21, 1974
/JHAA/	AN	Richard B. Resnick et al., "Naloxone Precipitated Withdrawal: A Method For Rapid Induction Onto Naltrexone," Clinical Pharmacology and Therapeutics, Volume 21, Number 4, pp. 409-413; received for publication November 16, 1976
/JHAA/	AO	Barbara A. Judson et al., "The Naloxone Test Opiate Dependence," Clin. Pharmacol. Ther., Vol. 27, Number 4, pp. 492-501, received for publication September 15, 1979
/JHAA/	AP	Philip D. Kanof et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects," The Journal of Pharmacology and Experimental Therapeutics, Vol. 260, No. 1, pp. 355-363, 1992
/JHAA/	AQ	Richard L. Wiesen et al., "The Safety and Value of Naloxone as a Therapeutic Aid," Drug and Alcohol Dependence, 2 (1977) pp. 123-130
	AR	
	AS	

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED 08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133CON2		SERIAL NO.: 10701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Benjamin OSHLACK et al.			
				FILING DATE: October 21, 2003		GROUP: 1616	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/JHAA/	AA 6 6 2 7 6 3 5	09/03	Palermo et al.	514	282		
	AB 6 6 9 6 0 6 6	02/04	Kaiko et al.	424	400		
	AC 6 4 7 5 4 9 4	11/02	Kaiko et al.	424	400		
	AD 7 1 4 4 5 8 7	12/06	Oshlack et al.	424	490		
	AE 6 0 0 4 9 7 0	12/99	O'Malley et al.	514	282		
	AF 6 1 2 0 8 0 6	9/00	Whitmire	424	497		
	AG 6 5 7 9 5 3 6	06/03	Hirsch et al.	424	484		
	AH 6 6 0 8 0 7 5	08/03	Foss et al.	514	282		
/JHAA/	AI 6 7 1 6 4 4 9	04/04	Oshlack et al.	514	002		
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	AJ						
	AK						
	AL						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
EXAMINER /James Alstrum Acevedo/				DATE CONSIDERED 08/18/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO 1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CON2SERIAL NO.:
10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
/JHAA/	AH	1 3 9 0 7 7 2	04/16/1975	GB	A61K31	485		
	AI							
	AJ							
	AK							
	AL							

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	


EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CON2SERIAL NO.:
10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	AA	4	5	8	7	1	1	8	05/06/1986	Hsiao	424	459	
	AB	6	6	9	6	0	6	6	02/24/2004	Kaiko et al.	424	400	
	AC	6	6	9	6	0	8	8	02/24/2004	Oshlack et al.	424	465	
/JHAA/	AD	6	7	1	6	4	4	9	04/06/2004	Oshlack, et al.	424	449	
	AE												
	AF												
	AG												

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
/JHAA/	AH	04	0	5	2	3	4	6	06/24/04	WO (A1)	A61K	9/62		
/JHAA/	AI	0	5	4	8	4	4	8	09/06/2000	EP (B1)	A61K	9/50	abstract	
	AJ													
	AK													
	AL													


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER /James Alstrum Acevedo/

DATE CONSIDERED
08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133CON2SERIAL NO.:
10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Benjamin OSHLACK et al.FILING DATE:
November 4, 2003GROUP:
1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	AA	4	5	8	7	1	1	8	05/06/1986	Hsiao	424	459	
	AB	6	6	9	6	0	6	6	02/24/2004	Kaiko et al.	424	400	
	AC	6	6	9	6	0	8	8	02/24/2004	Oshlack et al.	424	465	
/JHAA/	AD	6	7	1	6	4	4	9	04/06/2004	Oshlack, et al.	424	449	
	AE												
	AF												
	AG												

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
08/18/2007	AH	04	0	5	2	3	4	6	06/24/04	WO (A1)	A61K	9/62		
/JHAA/	AI	0	5	4	8	4	4	8	09/06/2000	EP (B1)	A61K	9/50	abstract	
	AJ													
	AK													
	AL													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

EXAMINER /James Alstrum Acevedo/

DATE CONSIDERED
08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133SERIAL NO.:
~~00781,081~~ 10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Oshlack, et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	AA	3	9	6	5	2	5	6		06/22/1976	Leslie	424	22	
	AB	4	2	3	7	1	4	0		12/02/1980	Dudzinski	424	260	
	AC	4	3	6	6	3	1	0		12/28/1982	Leslie	536	56	
	AD	4	4	4	3	4	2	8		04/17/1984	Oshlack, et al.	424	22	
	AE	4	8	2	8	8	3	6		05/09/1989	Elger, et al.	424	419	
	AF	4	8	3	4	9	6	5		05/30/1989	Martani, et al.	424	488	
	AG	4	8	3	4	9	8	4		05/30/1989	Goldie, et al.	424	488	
	AH	4	8	3	4	9	8	5		05/30/1989	Elger, et al.	424	488	
	AI	4	8	4	4	9	0	7		07/04/1989	Elger, et al.	424	465	
/JHAA/	AJ	4	8	4	4	9	0	9		07/04/1989	Goldie, et al.	424	480	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
Not Provided	AK	0	1	9	9	5	5	5		09/03/1986	Europe (A3)	A61K	31/615		
	AL	0	3	1	9	2	4	3		06/07/1989	Europe (A1)	A61K	31/485		
	AM	0	3	1	9	2	4	3		11/07/1990	Europe (A2)	A61K	31/485		
Not Provided	AN	0	0	0	1	5	7	7		01/13/2000	WO	A61K	31/00		
	AO	9	0	0	4	9	6	5		05/17/1990	WO	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AP	Translation of previously submitted German patent application DE 43 25 465
Not Provided	AQ	Alvarez Fuentes, et al., "Effectiveness of Repeated Administration of a New Oral Naltrexone Controlled-Release System on Morphine Analgesia"; J. Pharm Pharmacol (2001), 53; pg. 1201-1205
	AR	Alvarez Fuentes, et al., "Preclinical Study of an Oral Controlled Release Naltrexone Complex in Mice"; J. Pharm Pharmacol (2000), 52; pg. 659-663

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 69784.001 10/701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	BA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/		4 8 4 4 9 1 0	07/04/1989	Leslie, et al.	424	494	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	BB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Not Provided	BC	Archer, Sydney; "Historical Perspective on the Chemistry and Development of Naltrexone"; Naltrexone: Research Monograph 28 (1980) pg. 3-9					
	BD	Baum, et al., "The Impact of the Addition of Naloxone on the Use and Abuse of Pentazocine", Public Health Reports (1987) Vol. 102, No. 4 pg. 426-429					
	BE	Repake, et al., "Discovery of Novel Opioid Medications", NIDA Research Monograph 147 (1993) pg. 55-63					
	BF	Bloom, et al., "Clinical Studies with Naloxone/Methadone in a Ratio of 1:20"; 5th National Conference on Methadone Treatment (1973) Vol 2, pg. 1342 - 1349					
	BG	Blackly, M.D., "Naloxone in Opiate Addiction"; Current Psychiatric Therapies (1976) pg. 309-313					
	BH	Briscoe, et al., "Methoclopramide: Time Course of Changes in Alfentanil-Reinforced Responding in Rhesus Monkeys"; Psychopharmacology (2000) 148: pg. 393-399					
	BI	Abstract of Bromm, et al., "A Sensitive Method to Evaluate Effects of Analgesics in Man"; Meth and Find Exptl Clin Pharmacol 5 (6) (1983) pg. 545-551					
	BJ	Dillingham, et al., "Clinical Pharmacokinetics of Narcotic Agonist-Antagonist Drugs"; Clinical Pharm. (1985) 6: 332-343					
	BK	Calimlin, et al., "Effect of Naloxone on the Analgesic Activity of Methadone in a 1:10 Oral Combination"; Clin Pharmacol and Ther. (1974) Vol. 15; No. 6 pg. 556-564					
	BL	Caruso, et al., "Methadone and Naloxone in Combination (Naldone®) for the Treatment of Heroin Addicts"; Bristol Laboratories, pg. 1336-1341F					
	BM	Cherny, Nathan I., "Opioid Analgesics"; Drugs (1996) May; 51 (5) pg. 713-737					
	BN	Chiang, et al., "Clinical Evaluation of a Naltrexone Sustained-Release Preparation"; Drug and Alcohol Dependence (1983) 10, pg. 1-8					
	BO	Chiang, et al., "Kinetics of a Naltrexone Sustained-Release Preparation"; Clin. Pharmacol Ther. (1984) Vol. 36, No. 5, pg. 704-708					
	BP	Comer, et al., "Dose-Related Long-lasting Antagonism of the effects of heroin in humans"; Psychopharmacology (2002) 159, pg. 351-360					
Not Provided	BQ	Crabtree, et al., "Review of Naltrexone, a long-acting opiate antagonist"; Clinical Pharmacy, Vol 3 (1984) pg. 273-280					
EXAMINER /James Alstrum Acevedo/				DATE CONSIDERED 08/18/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 68781-081 10/701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.		FILING DATE: February 8, 2001	
				GROUP: 1615			
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	CA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	CA	4 8 6 7 9 8 5	09/19/1989	Heafield, et al.	424	461	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	CB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Not Provided	CC	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 82 (1999) pg. 1-11					
	CD	Crain et al., "Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability"; Dept. Of Neuroscience, Albert Einstein College of Medicine, Pain 84 (2000) pg. 121-131					
	CE	Fink, et al., "Naloxone in Heroin Dependence", Clin Pharm and Therapeutics, Vol 9, No. 3, pg. 308-377					
	CF	Fishman, et al., "Disposition of Naloxone-7,8-³H in Normal & Narcotic-Dependent Men"; J. of Pharm. and Experimental Therapeutics (1973) Vol 187, No. 3, pg. 575-580					
	CG	Fraser, Albert D., et al., "Clinical Toxicology of Drugs Used in the Treatment of Opiate Dependence", Clinical Toxicology 1, (1990) Vol 10, No. 2, pg. 375-386					
	CH	Freye, et al., "Effects of Tramadol and Tilidine/Naloxone on Oral Cerebral Transit & Pupillary Light Reflex", Arzneim.-Forsch/Drug Res. 50 (I) (2000) pg. 24-30					
	CI	Fudala, et al., "Effects of Buprenorphine and Naloxone in Morphine Stabilized Opioid Addicts"; Drug and Alcohol Dependence 50 (1998) pg. 1-8					
	CJ	Fudala, et al., "Human Pharmacology and Abuse Potential of Nalmefene", Clin Pharm and Thera (1991) Vol 49, 3, pg. 300-308					
	CK	Gul, et al., "Prolonged Blockade of Opioid Effect with Oral Nalmefene"; Clin Pharmacol Ther. (1986) pg. 537-542					
	CL	Gerra, et al., "Clonidine and Opiate Receptor Antagonists in the Treatment of Heroin Addiction", J. Substance Abuse Treatment (1993) Vol 12, 1, pg. 35-41					
	CM	Ghodse, et al., "Opioid analgesics and narcotic antagonists"; Side Effects of Drugs (2000) Annual 23, Ch. 8, pg. 96-113					
	CN	Glatt, William, M.D. FAGP, "A New Method for Detoxifying Opioid-Dependent Patients", J. Substance Abuse Treatment (1999) Vol 17, No 3, pg. 193-197					
	CO	Gold, et al., "Rapid Opioid Detoxification during General Anesthesia"; Anesthesiology (1999) Vol 91, No 6, 1059-1067					
Not Provided	CP	Greenwald, et al., "Comparative Clinical Pharmacology of Short-Acting Mu Opioids in Drug Abusers"; J. Pharm. and Experimental Therapeutics (1996) Vol 277, No 3, pg. 1228-1236					
EXAMINER /James Alstrum Acevedo/				DATE CONSIDERED 08/18/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,001 10/701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	DA	4 9 4 0 5 8 7	07/10/1990	Jenkins, et al.	424	480	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	DB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Not Provided	DC	Gupta, et al., "Morphine Combined with Dexampran or Naloxone", Anesthesia (1974) Vol 29 pg. 33-39					
	DD	Richter, et al., "Clinical Investigation on the Development of Dependence during Oral Therapy with Tramadol", Arzneimittel-Forsch/Drug Res. 35 (No II) (1985) pg. 1742-1744					
	DE	Rosen, et al., "Effect of Clonidine Pretreatment on Naloxone-Precipitated Opiate Withdrawal", J. of Pharm. and Experimental Ther. (1996) Vol 276, No 3, pg. 1128-1135					
	DF	Rosen, et al., "The effect of lamotrigine on naloxone-precipitated opiate withdrawal", Drug and Alcohol Dependence (1998) Vol 52, pg. 173-176					
	DG	Rosen, et al., "A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal", European J. of Pharm. (1996) Vol 307, pg. 251-257					
	DH	Schuh, et al., "Buprenorphine, Morphine and Naloxone Effects during Ascending Morphine Maintenance in Humans", J. of Pharm. and Experimental Ther. (1996) Vol 278, 2, pg. 836-846					
	DI	Schuh, et al., "Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans", Psychopharmacology (1999) Vol 145, pg. 162-174					
	DJ	Stevens, et al., "Nonspecific Excitatory Effects of Morphine: Reverse-Order Precipitated Withdrawal and Dose-Dose Interactions", Psychopharmacology (1981) Vol 75, pg. 210-211					
	DK	Sime, et al., "Reduction of Opiate Withdrawal-like Symptoms by Cocaine Abuse during Methadone and Buprenorphine Maintenance", Am. J. Drug Alcohol Abuse (1994) Vol 20, (4), pg. 445-458					
	DL	Sime, et al., "Use of Drug Combinations in Treatment of Opioid Withdrawal", J. of Clinical Psych. (1992) Vol 12, No. 3, pg. 203-209					
	DM	Stoller, et al., "Effects of buprenorphine/naloxone in opioid-dependent humans", Psychopharmacology (2001) Vol 154, pg. 230-242					
	DN	Strain, et al., "Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers", J. of Pharm. and Experimental Ther. (1992) Vol 261, No. 3, pg. 985-993					
	DO	Strain, et al., "Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers", Psychopharmacology (2000) Vol 148, pg. 374-383					
	DP	Strain, et al., "Precipitated Withdrawal by Pentazocine in Methadone Maintained Volunteers", J. of Pharm. and Experimental Ther. (1993) Vol 267, No 2, pg. 624-634					
	Not Provided	DQ	Tai, et al., "Naltrexone: An Antagonist Therapy for Heroin Addiction", NIDA (1997) 5 pages				
DR		Umbrecht, et al., "Naltrexone shortened opioid detoxification with buprenorphine", Drug and Alcohol Dependence (1999) Vol 56, pg. 181-190					
EXAMINER: /James Alstrum Acevedo/				DATE CONSIDERED 08/18/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/784,081 10/701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	EA	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/		4 9 7 0 0 7 5	11/13/1990	Oshlack	424	451	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	EB						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Not Provided	EC	Vaccaro, et al., "Endogenous Opiates: 1000", Peptides 31 (2000) pg. 1076-1074					
	ED	Wang, et al., "Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence"; J. of Neurochemistry (2001) Vol 77, pg. 1590-1600					
	EE	Way, et al., "Responsivity to Naloxone during Morphine Dependence"; Annals New York Academy of Sciences, pg. 252-261					
	EF	Weinberg, et al., "Sublingual absorption of selected opioid analgesics"; Clin Pharm Ther (1988) Vol 44, No 3, pg. 335-342					
	EG	Wells, et al., "In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid μ-Agonists/δ-Antagonist that Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence"; J. Pharm and Exper. Thera. (2001) Vol 297, No 2, pg. 597-605					
	EH	Wodak, Alex, "Drug Treatment for Opioid Dependence"; Australian Prescriber (2001) Vol 24, No 1, pg. 4-6					
	EI	Wright, et al., "Acute physical dependence in humans, repeated naloxone-precipitated withdrawal after a single dose of methadone"; Drug and Alcohol Dependence (1991) Vol 27, pg. 139-148					
	EJ	Zhu, et al., "Naloxone-precipitated morphine withdrawal in infant rat is attenuated by acute administration of NOS inhibitors but not NMDA receptor antagonists"; Psychopharmacology (2000) Vol 150, pg. 325-336					
	EK	Han, et al., "Mucoadhesive buccal disks for novel nalbuphine prodrug controlled delivery: effect of formulation variables on drug release and mucoadhesive performance"; International J. of Pharm (1999) Vol 177, pg. 201-209					
	EL	Handel, et al., "Naloxone"; Annals of Emergency Medicine (1983) Vol 13, pg. 438-445					
	EM	Harris, et al., "Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine"; Drug and Alcohol Dependence (2000) Vol 61, pg. 85-94					
	EN	Hawkes, et al., "Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine"; Aliment Pharm Ther (2001) Vol 15, pg. 625-630					
Not Provided	EO	Hogget, et al., "Comparison of tilidine/naloxone, tramadol and brenferone in experimental pain: a double blind randomized crossover study in healthy human volunteers"; International J. Clin Pharm and Ther (1999) Vol 37, No 8, pg. 377-385					
EXAMINER /James Alstrum Acevedo/				DATE CONSIDERED 08/18/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09704-001 10/30/041								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 8, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	FA	FB	FC	FD	FE	FF	FG	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/JHAA/								4 9 8 7 1 3 6	01/22/1991	Kreek, et al.	514	282		
								4 9 9 0 3 4 1	02/05/1991	Goldie, et al.	424	484		
								5 0 7 1 6 4 6	12/10/1991	Malkowska, et al.	424	497		
								5 0 9 1 1 8 9	02/25/1992	Heafield, et al.	424	457		
								5 2 1 5 7 5 8	06/01/1993	Krishnamurthy	424	488		
								5 2 2 6 3 3 1	07/13/1993	Thompson, et al.	73	865.9		
/JHAA/								5 2 6 6 3 3 1	11/30/1993	Oshlack, et al.	424	468		
FOREIGN PATENT DOCUMENTS														
								DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
Not Provided OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
								FI	Budd, Keith, "Clinical Use of Opioid Antagonists", <i>Baltimore's Clinical Anesthesiology</i> (1987) Vol 1, No 4, pg. 998-1014					
								FJ	Crain, et al., "Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment"; <i>Proc. Natl. Acad. Sci</i> (1995) Vol 92, pg. 10540-10544					
								FK	Nowes, et al., "The Pharmacology of TR5100, a New Narcotic Agonist/Antagonist Analgesic", <i>NIDA Research</i> (1979) pg. 99-105					
								FL	Leeling, et al., "Disposition and metabolism of codeine in the rat, dog and man", <i>Drug Metabolism and Disposition</i> (1982) Vol 10, No 6, pg. 649-653					
								FM	Amass, et al., "Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine-naloxone tablet", <i>Drug and Alcohol Dependence</i> (2000) Vol 58, pg. 143-152					
								FN	Russell, et al., "Buccal and oral bioavailability of naloxone and naltrexone in rats", (1987) Vol 30, pg. 127-130					
								FO	Jasinski, et al., "The human pharmacology and abuse potential of N-allylnoroxymorphone naloxone", <i>J. of Pharm and Exper Ther</i> (1987) Vol 157, No. 2, pg. 420-426					
								FP	Jones, et al., "Nalmefene: blockade of intravenous morphine challenge effects in opioid-abusing humans", <i>Drug and Alcohol Dependence</i> (2000) Vol 60, pg. 29-37					
								FQ	Kandl, et al., "Clinical Characteristics of Naloxone-Precipitated Withdrawal in Human Opioid-Dependent Subjects", <i>J. of Pharm and Exper Ther</i> (1992) Vol 260, No. 1, pg. 355-363					
								FR	King, et al., "Naltrexone Biotransformation and Incidence of Subjective Side Effects: A Preliminary Study", <i>Alcoholism, Clin and Exp Res</i> (1997) Vol 21, No. 5, pg. 906-909					
Not Provided EXAMINER /James Alstrum Acevedo/									DATE CONSIDERED 08/18/2007					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 10/31,041								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 8, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/JHAA/	GA	5	2	8	6	4	9	3	02/15/1994	Oshlack, et al.	424	468		
	GB	5	3	2	4	3	5	1	06/28/1994	Oshlack, et al.	106	153		
	GC	5	3	3	6	6	9	1	08/09/1994	Raffa, et al.	514	629		
	GD	5	3	5	6	4	6	7	10/18/1994	Oshlack, et al.	106	153		
	GE	5	4	1	1	7	4	5	05/02/1995	Oshlack, et al.	424	456		
	GF	5	4	6	0	8	2	6	10/24/1995	Merrill, et al.	424	470		
/JHAA/	GG	5	4	7	2	7	1	2	12/05/1995	Oshlack, et al.	424	480		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
Not Provided	GH	0	7	0	1	2	0	2	03/12/1967	WO	A61K	31/485		
	GI	0	1	3	2	1	0	0	03/10/2001	WO (A2)	A61K	31/485		
	GL	0	1	6	8	0	8	0	09/20/2001	WO (A2)	A61K	31/00		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
Not Provided	GK	Kogan, et al., "Estimation of the Systemic Availability and other Pharmacokinetic Parameters of Naltrexone in Man after Acute and Chronic Oral Administration"; Res. Comm. in Chem. Path. and Pharm (1977) Vol 18, No. 1, pg. 29-34												
	GL	Kosten, Thomas R., M.D., "Buprenorphine for Benzodiazepine-Abusing Heroin Addicts", Amer J. of Psychiatry (1994) Vol 1, pg. 151												
	GM	Kosten, et al., "Opioid antagonist challenges in buprenorphine maintained patients"; Drug and Alcohol Dependence (1990) Vol 25, pg. 73-78												
	GN	Kurland, et al., "Naloxone and the Narcotic Abuser: A Controlled Study of Partial Blockade", Intern J. of the Addictions (1974) Vol 9, No. 5, pg. 663-672												
	GO	Loe, et al., "Naloxophine Co-administered with Morphine Prevents Tolerance and Dependence"; Anesth Analg (1997) Vol 84, pg. 810-815												
	GP	Lehmann, et al., "Influence of Naloxone on the Postoperative Analgesic and Respiratory Effects of Buprenorphine", Eur J. Clin. Pharm. (1988) Vol 34, 343-352												
Not Provided	GQ	Levine, et al., "Potentiation of Pentazocine Analgesia by Low-dose Naloxone", J Clin Invest. (1988) Vol 82, pg. 1574 - 1577												
EXAMINER /James Alstrum Acevedo/										DATE CONSIDERED 08/18/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 00/781,081 10/701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.			
				FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/JHAA/	HA	5 4 7 8 5 7 7	12/26/1995	Sackler, et al.	424	489	
	HB	5 5 0 0 2 2 7	03/19/1996	Oshlack, et al.	424	476	
	HC	5 5 0 8 0 4 2	04/16/1996	Oshlack, et al.	424	468	
	HD	5 5 0 8 0 4 3	04/16/1996	Krishnamurthy	424	484	
	HE	5 5 4 9 9 1 2	08/27/1996	Oshlack, et al.	424	468	
	HF	5 5 5 2 4 2 2	09/03/1996	Gauthier, et al.	514	368	
	HG	5 5 9 1 4 5 2	01/07/1997	Miller, et al.	424	468	
	HH	5 6 0 1 8 4 5	02/11/1997	Buxton, et al.	424	495	
	HI	5 6 2 2 7 2 2	04/22/1997	Knott, et al.	424	494	
/JHAA/	HJ	5 6 3 9 4 7 6	06/17/1997	Oshlack, et al.	424	468	
FOREIGN PATENT DOCUMENTS							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	HK						
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Not Provided	HL	Loimer, et al., "Combined Naloxone/Methadone Preparations for Opiate Substitution Therapy"; <u>J. of Substance Abuse Treatment</u> (1991) Vol 8, pg. 157-160					
	HM	Martin, et al., "Bioavailability Investigation of a New Tilidine/Naloxone Liquid Formulation Compared to a Reference Formulation"; <u>Arzneim.-Forsch./Drug Res.</u> (1999) Vol 49, pg. 599-607					
	HN	Martin, et al., "Demonstration of Tolerance to and Physical Dependence on N-allylnormorphine (Nalorphine)"; <u>J. of Pharm and Exper. Thera</u> (1965) Vol 150, No. 3, pg. 437-442					
	HO	Mendelson, et al., "Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine stabilized, opiate dependent volunteers"; <u>Psychopharmacology</u> (1999) Vol 141, pg. 37-46					
	HP	Mendelson, et al., "Buprenorphine and Naloxone Interactions in Methadone Maintenance Patients"; <u>Society of Biological Psychiatry</u> (1997) Vol 41, pg. 1095-1101					
	HQ	Nutt, et al., "Methadone-naloxone mixtures for use in methadone maintenance programs"; <u>Clin. Pharma and Thera</u> , Vol 15, No. 2, pg. 156-166					
Not Provided	HR	Parwankar, et al., "Methadone-naloxone in combination for the treatment of heroin addicts"; <u>Clin. Pharma and Thera</u> , Vol 14, No. 6, pg. 941-948					
EXAMINER /James Alstrum Acevedo/			DATE CONSIDERED 08/18/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,001 101701,041								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 8, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	LA	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/JHAA/	LA	5	6	5	6	2	9	5	08/12/1997	Oshlack, et al.	424	468		
	IB	5	6	7	0	1	7	2	09/23/1997	Buxton, et al.	424	495		
	IC	5	6	7	2	3	6	0	09/30/1997	Sackler, et al.	424	490		
	ID	5	6	8	1	5	8	5	10/28/1997	Oshlack, et al.	424	494		
	IE	5	7	6	3	4	5	2	06/09/1998	Miller, et al.	514	282		
	IF	5	7	8	0	4	7	9	07/14/1998	Kim	514	282		
	IG	5	8	1	1	1	2	6	09/22/1998	Krishnamurthy	424	498		
	IH	5	8	3	4	4	7	7	11/10/1998	Mioduszewski	514	282		
/JHAA/	II	5	8	4	3	4	8	0	12/01/1998	Miller, et al.	424	484		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	II													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
Not Provided	IK	Parvartikar, et al., "Naloxone-Methadone Combination for the Treatment of Opiate Dependence"; Missouri Institute of Psychiatry, pg. 1350-1354												
	IL	Pitts, et al., "Antinociceptive and Response Rate-Altering Effects of Kappa Opioid Agonists, Spiradoline, Enadoline and U69,593, Alone and in combination with Opioid Antagonists in Squirrel Monkeys"; J. Pharm and Exper Thera (1994) Vol 271, No. 3, pg. 1507-1508												
	IM	Preston, et al., "Bunrenorphine and Naloxone alone and in combination in opioid-dependent humans"; Psychopharmacology (1988) Vol 94, pg. 484-490												
	IN	Preston, et al., "Differential Naltrexone Antagonism of Hydromorphone and Pentazocine Effects in Human Volunteers"; J. Pharm and Exper Thera (1993) Vol 264, No. 2, pg. 813-823												
	IO	Preston, et al., "Effects of Sublingually given naloxone in opioid-dependent human volunteers"; Drug and Alcohol Dependence (1990), Vol 25, pg. 27-34												
Not Provided	IP	Bigelow, et al., "Abuse Liability Assessment of Bunrenorphine-Naloxone Combinations"; Dept. of Psychiatry and Behavioral Sciences - The Johns Hopkins University School of Medicine, pg. 145-149												
	IQ	Wikler, et al., "N-Allylnormorphine: Effects of single doses and precipitation of acute "Abstinence Syndromes" during addiction to morphine, methadone or heroin in man (post-addicts); N-Allylnormorphine During Narcotic Addiction (1953) pg. 8-20												
EXAMINER /James Alstrum Acevedo/										DATE CONSIDERED 08/18/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133

SERIAL NO.:

09/281,081 10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Oshlack, et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	JA	5	8	4	9	2	4	0	12/15/1998	Miller, et al.	264	460	
	JB	5	8	6	9	0	9	7	02/09/1999	Wong, et al.	424	473	
	JC	5	8	7	9	7	0	5	03/09/1999	Heafield, et al.	424	464	
	JD	5	8	9	1	4	7	1	04/06/1999	Miller, et al.	424	468	
	JE	5	9	0	8	8	4	8	06/01/1999	Miller, et al.	514	282	
	JF	5	9	5	8	4	5	2	09/28/1999	Oshlack, et al.	424	457	
	JG	5	9	5	8	4	5	9	09/28/1999	Chasin, et al.	424	490	
	JH	5	9	6	5	1	6	1	10/12/1999	Oshlack, et al.	424	457	
	JI	5	9	6	5	1	6	3	10/12/1999	Miller, et al.	424	468	
/JHAA/	JJ	5	9	6	8	5	5	1	10/19/1999	Oshlack, et al.	424	456	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	JK													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Not Provided	JL	Zaks, et al., "Naloxone Treatment of Opiate Dependence", JAMA (1971) Vol 215, No. 13, pg. 2108-2110
	JM	Barton, et al., "Intranasal Administration of Naloxone by Paramedics", Prehospital Emergency Care (2002) Vol 6, No. 1, pg. 54-58
	JN	Blachly, Paul, H., M.D., "Naloxone in Opiate Addiction", Current Psychiatric Therapies (1976) pg. 209-213
	JO	Bashaw, et al., "Relative bioavailability of controlled release oral morphine sulfate during naloxone blockade", Int'l J. of Clin Pharm and Thera (1995) Vol 33, No. 9, 524-529
	JP	Jasinski, D.R., "Assessment of the Abuse Potential of Morphinelike Drugs (Methods Used in Man)", Drug Addiction (1997) pg. 197-258
Not Provided	JQ	Johnson, et al., "Buprenorphine and Naloxone for Heroin Dependence", Substance Use Disorders (2000) pg. 519-526
	JR	Strom, et al., "Opioid antagonist effects of desomine in opioid dependent humans", Clin Pharm and Thera (1996) Vol 60, No. 3, pg. 206-217

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781,081 10/701,041								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 8, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL	CLASS	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/JHAA/	KA	6	0	2	4	9	8	2	02/15/2000	Oshlack, et al.	424	476		
	KB	6	0	6	8	8	5	5	05/30/2000	Leslie, et al.	424	468		
	KC	6	0	7	7	5	3	2	06/20/2000	Malkowska, et al.	424	457		
	KD	6	0	7	7	5	3	3	06/20/2000	Oshlack, et al.	424	461		
	KE	6	1	0	3	2	5	8	08/15/2000	Simon	424	449		
	KF	6	1	0	3	2	6	1	08/15/2001	Chasin, et al.	424	459		
	KG	6	1	4	3	3	2	2	11/07/2000	Sackler, et al.	424	459		
	KH	6	1	4	3	3	2	8	11/07/2000	Heafield, et al.	424	489		
	KI	6	1	6	2	4	6	7	12/19/2000	Miller, et al.	424	468		
	KJ	6	2	1	0	7	1	4	04/03/2001	Oshlack, et al.	424	476		
	KK	6	2	5	4	8	8	7	07/03/2001	Miller, et al.	424	468		
	KL	6	2	6	1	5	9	9	07/17/2001	Oshlack, et al.	424	457		
/JHAA/	KM	6	2	9	4	1	9	5	09/25/2001	Oshlack, et al.	424	457		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
Not Provided	KN	0	1	3	7	7	8	5	05/31/2001	WO (A2)	A61K			
	KO	0	1	5	2	0	5	1	07/26/2001	WO (A1)	A61K	31/483		
Not Provided	KP	0	1	8	3	2	3	7	11/15/2001	WO (A2)	A61P			
	KQ	0	1	0	3	0	5	2	12/13/2001	WO (A2)	A61K	31/700		
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
Not Provided	KR	Preston, et al., "Abuse liability studies of opioid agonist-antagonists in humans", Drug and Alcohol Dependence (1991) Vol 28, pg. 49-82												
	KS	Brennscheidt, et al., "Pharmacokinetics of Nortilidine and Naloxone after Administration of Tilidine/Naloxone Solution or Tilidine/Naloxone Sustained Release Tablets"; Arzneim.-Forsch/Drug Res. (2000) Vol 50, pg. 1015-1022												
EXAMINER /James Alstrum Acevedo/										DATE CONSIDERED 08/18/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 08/781,081 10/701,041								
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Oshlack, et al.										
				FILING DATE: February 8, 2001		GROUP: 1615								
U.S. PATENT DOCUMENTS														
*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
/JHAA/	LA	6	3	0	6	4	3	8	10/23/2001	Oshlack, et al.	424	468		
	LB	6	3	2	6	0	2	7	12/04/2001	Miller, et al.	424	468		
	LC	6	3	3	5	0	3	3	01/01/2002	Oshlack, et al.	424	457		
	LD	6	3	7	5	9	5	7	04/23/2002	Kaiko, et al.	424	400		
	LE	6	3	8	7	4	0	4	05/14/2002	Oshlack, et al.	424	480		
	LF	6	3	9	9	0	9	6	06/04/2002	Miller, et al.	424	464		
/JHAA/	LG	6	4	7	5	4	9	4	11/05/2002	Kaiko, et al.	424	400		
FOREIGN PATENT DOCUMENTS														
		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	LH													
	LI													
	LJ													
	LK													
	LL													
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)														
	LM													
	LN													
	LO													
	LP													
EXAMINER /James Alstrum Acevedo/										DATE CONSIDERED 08/18/2007				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.														

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09/781,081 10/701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)						APPLICANT(S): Curtis Wright et al.			
						FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS									
*EXAMINE R INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE			
/JHAA/	AA 5 9 9 8 4 3 4	12/99	Mitch et al.	514	210.16				
	AB 5 9 7 2 9 5 4	10/99	Foss	514	282				
	AC 5 9 6 8 5 4 7	10/99	Reder et al.	424	449				
	AD 5 9 4 2 2 4 1	8/99	Chasin et al.	424	426				
	AE 5 8 8 0 1 3 2	3/99	Hill	514	282				
	AF 5 8 6 6 1 6 4	2/99	Kuczynski et al.	424	472				
	AG 5 8 6 0 9 5 0	1/99	Demopoulos et al.	604	49				
	AH 5 8 5 8 0 1 7	1/99	Demopoulos et al.	604	890.1				
	AI 5 7 6 7 1 2 5	6/98	Crain et al.	514	282				
	AJ 5 6 3 3 2 5 9	5/97	Qin et al.	514	282				
/JHAA/	AK 5 6 2 4 9 3 2	4/97	Qin et al.	514	282				
FOREIGN PATENT DOCUMENTS									
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
					YES	NO			
/JHAA/ AL 19 6 5 1 5 5 1	6/98	DE	A61K	31/485					
AM 29 7 1 9 7 0 4	2/97	DE	A61K	31/485					
AN 4 3 2 5 4 6 5	2/95	DE	A61K	31/485	X				
AO 2 2 2 2 0 3 9	11/72	DE	A61K	27/00					
/JHAA/ AP 0 9 1 3 1 5 2	6/99	EP	A61K	31/485					
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
Not Provided	AD	Abstract, Cancer Chemother Pharmacol (1996), 42(4):267-91.							
	AR	Yuan et al., Drug and Alcohol Dependence (1996), 52:161-165.							
	AS	Gao et al., "Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient Administered Morphine Sulfate," Anesthesiology (1997), 87(5):1075-1080.							
EXAMINER /James Alstrum Acevedo/			DATE CONSIDERED 08/18/2007						
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133

SERIAL NO.:

~~00781,081~~ 70/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Curtis Wright et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	BA	5	6	1	6	6	0	1	4/97	Khanna et al.	514	399	
	BB	5	5	8	5	3	4	8	12/96	Crain et al.	514	12	
	BC	5	5	8	0	8	7	6	12/96	Crain et al.	514	282	
	BD	5	5	7	8	7	2	5	11/96	Portoghese et al.	546	35	
	BE	5	5	7	4	0	5	2	11/96	Rose et al.	514	343	
	BF	5	5	5	6	8	3	8	9/96	Mayer et al.	514	25	
	BG	5	5	3	4	4	9	2	7/96	Aston et al.	514	608	
	BH	5	5	1	4	6	8	0	5/96	Weber et al.	514	249	
	BI	5	5	1	2	5	7	8	4/96	Crain et al.	514	282	
	BJ	5	5	0	2	0	5	8	3/96	Mayer et al.	514	289	
/JHAA/	BK	5	4	8	6	3	6	2	1/96	Kitchell et al.	424	426	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
Not Provided	BL	0	6	4	7	4	4	8	4/95	EP	A61K	31/485		
	BM	0	3	5	2	2	6	1	1/88	EP	A61K	31/485		
	BN	0	2	0	3	2	8	2	12/86	EP	A61K	9/22		
Not Provided	BO	0	0	0	2	1	2	0	7/93	WO	A61K	31/485		
	BP	9	8	3	5	6	7	9	8/98	WO	A61K	31/485		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Not Provided	BU	Shen et al., "Ultra Low Doses of Naltrexone or Etorphine Increase Morphine's Antinociceptive Potency and Attenuate Tolerance/Dependence in Mice," Brain Research (1997), 757:176-190.
	BR	Yuan et al., Clinical Trials and Therapeutics (1997), 61:467-475.

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133SERIAL NO.:
~~09/781,001~~ 10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Curtis Wright et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	CA	5	4	7	2	9	4	3		12/95	Crain et al.	514	12	
	CB	5	4	5	7	2	0	8		10/95	Portoghese et al.	546	35	
	CC	5	4	2	6	1	1	2		6/95	Zagon et al.	514	282	
	CD	5	3	7	6	6	6	2		12/94	Ockert	514	282	
	CE	5	3	5	6	9	0	0		10/94	Bihari et al.	514	282	
	CF	5	3	5	2	6	8	3		10/94	Mayer et al.	514	289	
	CG	5	3	5	2	6	8	0		10/94	Portoghese et al.	514	279	
	CH	5	3	2	1	0	1	2		6/94	Mayer et al.	514	25	
	CI	5	3	1	7	0	2	2		5/94	Borsodi et al.	514	282	
	CJ	5	3	1	6	7	5	9		5/94	Rose et al.	424	10	
/JHAA/	CK	5	2	7	3	7	6	0		12/93	Oshlack et al.	424	486	

FOREIGN PATENT DOCUMENTS

Not Provided		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
														YES	NO
	CL	9	7	3	3	5	6	6		9/97	WO	A61K	9/20		
	CM	9	6	0	2	2	5	1		2/96	WO	A61K	31/485		
	CN	9	5	0	3	8	0	4		2/95	WO	A61K	31/485		
	CO	9	4	0	6	4	2	6		3/94	WO	A61K	31/46		
Not Provided	CP	8	3	0	3	1	9	7		9/83	WO	A61K	9/22		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	CQ	Mendelson J., et al., "Buprenorphine and Naloxone Interactions in Opiate-Dependent Volunteers," Clin. Phar. Ther. (1996), 60:105-114.
	CR	Walsh et al., "Effects of Naltrexone on Response to Intravenous Cocain, Hydromorphone and their Combination in Humans," (1996).

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133SERIAL NO.:
~~09781,001~~ 10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Curtis Wright et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	DA	5	2	5	6	6	6	9	10/93	Askanazi et al.	514	282	
	DB	5	2	3	6	7	1	4	8/93	Lee et al.	424	449	
	DC	5	2	2	5	4	4	0	7/93	London et al.	514	535	
	DD	5	1	4	9	5	3	8	9/92	Granger et al.	424	449	
	DE	5	1	0	2	8	8	7	4/92	Goldberg	514	282	
	DF	5	0	9	6	7	1	5	3/92	Sinclair	424	449	
	DG	5	0	8	6	0	5	8	2/92	Sinclair et al.	514	282	
	DH	5	0	7	5	3	4	1	12/91	Mendelson et al.	514	282	
	DI	4	9	3	5	4	2	8	6/90	Lewis	514	282	
	DJ	4	8	8	9	8	6	0	12/89	Rzeszutarski et al.	514	282	
/JHAA/	DK	4	8	8	2	3	3	5	11/89	Sinclair	514	282	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	DL													

Not

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Provided

	DM	Chin-Cheng Chien, Neuroscience Letters 190 (1995), 137-139.
	DN	Crain et al., "Ultra-Low Concentrations of Naloxone Selectively Antagonize Excitatory Effects of Morphine on Sensory Neurons, Thereby Increasing Its Antinociceptive Potency and Attenuating Tolerance/Dependence During Chronic Cotreatment," Proc. Natl. Acad. Sci. USA (1995), 92:10540-10544.
	DO	Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington's Science and Practice of Pharmacy (1995), 2:1207.
Not	DP	Physician's Desk Reference 48th Ed. (1994) Montvale, NJ, 2120-2121.
Provided	DQ	Foss et al., J. Clin Pharmacol (1995), 35:747-751.

EXAMINER
/James Alstrum Acevedo/DATE CONSIDERED
08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133SERIAL NO.:
~~69781-081~~ 10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Curtis Wright et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINER R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	EA	4	8	7	3	0	7	6	10/89	Fishman et al.	412	10	
	EB	4	8	6	1	7	8	1	8/89	Goldberg	514	282	
	EC	4	8	6	1	5	9	8	8/89	Oshlack et al.			
	ED	4	8	0	6	5	5	8	2/89	Wuest et al.	514	381	
	EE	4	8	0	6	5	4	3	2/89	Choi	514	464	
	EF	4	8	0	6	3	4	1	2/89	Chien et al.	424	448	
	EG	4	8	0	3	2	0	8	2/89	Pasternak	514	282	
	EH	4	7	8	5	0	0	0	11/88	Kreek et al.	514	282	
	EI	4	7	6	9	3	7	2	9/88	Kreek et al.	514	282	
	EJ	4	7	6	0	0	6	9	7/88	Rzeszotarski et al.	514	282	
/JHAA/	EK	4	7	3	0	0	4	8	3/88	Portoghese et al.	546	45	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EL													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

NOT Provided	EM	Holmes et al., Anesth. Analg. (1988), 77:1166-70.
	EN	Mischewski et al., Brain Research (1982), 506:41-45.
	EO	Weinhold et al., "Buprenorphine Alone and In Combination with Naltrexone in Non-Dependent Humans," Drug and Alcohol Dependence (1992), 30:263-274.
	EP	Cappel et al., Pharma. Bioch. & Behav. (1983), 34:423-427.
	EQ	Vaccorino et al., Pain (1989), 36:103-109.
NOT Provided	ER	Gonzalez et al., "Naltrexone: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in the Management of Opioid Dependence," Drugs (1988), 35:192-213.

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133SERIAL NO.:
~~09/781,081~~ 10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Curtis Wright et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	FA	4	7	1	9	2	1	5	1/88	Goldberg	514	282	
	FB	4	6	6	1	4	9	2	4/87	Lewis et al.	514	282	
	FC	4	6	0	8	3	7	6	8/86	Pasternak	514	282	
	FD	4	5	8	2	8	3	5	4/86	Lewis et al.	514	282	
	FE	4	5	7	3	9	9	5	3/86	Chen et al.	604	896	
	FF	4	4	6	4	3	7	8	8/84	Hussain et al.	424	260	
	FG	4	4	5	7	9	3	3	7/84	Gordon et al.	424	260	
	FH	4	4	5	1	4	7	0	5/84	Ganti	424	260	
	FI	4	4	0	1	6	7	2	8/83	Portoghese et al.	424	260	
	FJ	4	1	7	6	1	8	6	11/79	Goldberg	424	260	
/JHAA/	FK	3	9	6	6	9	4	0	6/76	Pachter et al.	424	260	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	FL													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Not	FM	Sunshine, et al., "Analgesic Efficacy of Pentecocaine Versus a Pentecocaine Naloxone Combination Following Oral Administration," Clin. J. Pain (1988), 4:35-40.
Provided	FN	Wang et al., "Crossover and Parallel Study of Oral Analgesics," J. Clin. Pharmacol (1981), 21:162-166.
	FO	
	FP	
	FQ	
	FR	

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:
200.1133SERIAL NO.:
~~69/781,084~~ 10/701,041

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S):
Curtis Wright et al.FILING DATE:
February 8, 2001GROUP:
1615

U.S. PATENT DOCUMENTS

*EXAMINE R INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	GA	3	8	7	9	5	5	5	4/75	Pachter et al.	424	260	
	GB	3	7	7	3	9	5	5	11/73	Pachter et al.	424	260	
	GC	3	6	7	6	5	5	7	7/72	Lachman et al.	424	260	
	GD	3	4	9	3	6	5	7	2/70	Lewenstein et al.	424	260	
	GE	3	3	3	2	9	5	0	7/67	Blumberg et al.	260	285	
/JHAA/	GF	2	7	7	0	5	6	9	11/56	Fromherz et al.	167	65	
	GG												
	GH												
	GI												
	GJ												
	GK												

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	GL													

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	GM	
	GN	
	GO	
	GP	
	GQ	
	GR	
	GS	

EXAMINER

/James Alstrum Acevedo/

DATE CONSIDERED

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF PRIOR ART CITED BY APPLICANT

(Use several sheets if necessary)

APPLICANT(S): Curtis WRIGHT, et al.

FILING DATE: February 8,
2001

GROUP: 1615

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/JHAA/	AA	6 2 2 8 8 6 3	05/08/01	Palermo et al.	514	282	
/JHAA/	AB	6 2 7 7 3 8 4	08/21/01	Kaiko et al.	424	400	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
Not Provided	AG	WO 98 2 3 8 1 3	00/10/00	EPO	A61K	31/485	Abstract
	AD	WO 00 2 8 6 4 0	07/06/00	EPO	A61K	9/00	Abstract

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Not Provided	AE	Press Release entitled "International Patent Application To Be Published on Abuse-Resistant Pain Reliever Being Developed by Purdue Pharma" August 8, 2001.
	AF	Baron, et al., Increased Analgesic Potency of Mu Agonists after Continuous Naltrexone Infusion in Rats, J. Pharm. Exper. Ther. 1991 259(2) pg 582-589
	AG	Yabuta, et al., Supersensitivity to Opioid Analgesics Following Chronic Opioid Antagonist Treatment: Relationship to Receptor Selectivity, Pharmacol. Bio. Beh. 1995 51 (2) pg 535-539
	AH	Crain, et al., Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia, Brain Res. 2001 888 pg 75-82
	AI	Zhang, et al., Down-Regulation of μ-Opioid Receptors in Rat and Monkey Dorsal Root Ganglion Neurons and Spinal Cord After Peripheral Axotomy, Neuroscience 1998 82, pg 223-240
	AJ	Abdulla, et al., Axotomy reduces the effect of analgesic opioids yet increases the effect of nociceptin on dorsal root ganglion neurons, J. Neuro Sci 1998 18, pg 9685-9694
	AK	Di Ciano, et al., Orphanin FQ reduces morphine-induced dopamine release in the nucleus accumbens: a microdialysis study in rats, Neurosci. Lett. 1999 272, pg 183-186
Not Provided	AL	Cicciocioppo, et al., Effect of nociceptin/orphanin FQ on the rewarding properties of morphine, Eur. J. Pharmacol. 2000 404, pg 153-159
	AM	
	AN	

EXAMINER

/James Alstrom Acevedo/

08/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1133		SERIAL NO.: 09781-881 10/701,041	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)				APPLICANT(S): Curtis WRIGHT, et al.			
				FILING DATE: February 8, 2001		GROUP: 1615	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
Not Provided	AA	Denley, Function of Myocardial α-ADRENOCEPTORS. Life Sciences (1982) Vol. 31 pg 101-112					
	AB	Levine, et al., Potentiation of Pentazocine Analgesia by Low-dose Naloxone. J. Clin. Invest. (1988) Vol. 82 pg. 1574-1577					
	AC	Yoburn, et al. Opioid Antagonist-induced Receptor Upregulation: Effects of Concurrent Agonist Administration, (1994) [Publication Date], Brain Research Bulletin, Vol. 33 pg 237-240					
	AD	Bunzow, et al., Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ or κ opioid receptor type: FEBS Letters 347 (1994) pg. 284-288					
	AE	Mollereau, et al., ORL1, a novel member of the opioid receptor family: Cloning, functional expression and localization: FEBS Letters 341 (1994) pg. 33-38					
	AF	Wang, et al., cDNA cloning of an orphan opiate receptor gene family member and its splice variant. FEBS Letters 348 (1994) 75-79					
	AG	Suzuki, et al., Morphine conditioned place preference after chronic treatment with naloxone in the rat. Research Communications in Substances of Abuse. (1991) Vol. 12, No. 3 pg. 119-131					
EXAMINER /James Alstrum Acevedo/				DATE CONSIDERED 08/18/2007			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							